Home Featured

Featured

Latest

When it Comes to Psychedelic Access, It’s the Messenger, Not the Message

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson of Ambio Life Sciences

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote...

Accredited Entheogenic Seminary: Inside the Congregation for Sacred Practices with Paul...

Does Cannabis Research Deserve As Much Funding As Ibogaine Research?

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes...

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate...

Win 10 Groundbreaking Psychedelic Books – Our Giveaway with Inner Traditions!

Psychedelic Playhouse by District216

Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer...

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Dreamshadow Transpersonal Breathwork

12 3...290 Page 1 of 290

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.